New York, November 05, 2024 - PRISM MarketView - ZyVersa Therapeutics (NASDAQ: ZVSA) announced positive data highlighting the potential of its inflammasome inhibitor, IC 100, in preserving pancreatic islet beta cells and reducing inflammation-related damage that contributes to insulin resistance and type 2 diabetes. Published research showed that inhibiting the inflammasome NLRP3 pathway in an obesity model helped protect and restore beta cell function, improving overall metabolic health.
“We are excited about the potential of IC 100 to effectively control the inflammation of obesity. Unlike the NLRP3 inhibitors in development, IC 100 targets ASC to inhibit multiple inflammasomes, including NLRP3 and AIM2, which are activated in obesity. More importantly, IC 100 uniquely disrupts the function of ASC specks to attenuate the chronic, systemic inflammation leading to obesity comorbidities. We look forward to progressing IC 100’s obesity development program into phase 1 around mid-2025.”
Stephen C. Glover, ZyVersa’s CEO and President
This supports ZyVersa’s development of IC 100 as a complementary treatment to incretin therapies for managing obesity and related conditions. Following this news, ZyVersa’s stock rose by 41%.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities